Literature DB >> 15920496

Incidence and prognostic significance of karyotype abnormalities in de novo primary myelodysplastic syndromes: a study on 331 patients from a single institution.

P Bernasconi1, C Klersy, M Boni, P M Cavigliano, S Calatroni, I Giardini, B Rocca, R Zappatore, M Caresana, J Quarna, M Lazzarino, C Bernasconi.   

Abstract

The impact of clinical parameters, International Prognostic Scoring System (IPSS) scores/cytogenetic categories, and some single cytogenetic defects on overall survival (OS) and time to myelodysplastic syndromes (MDS)/AML progression (progression-free interval (PFI)) was evaluated in 331 MDS patients. Statistical analysis demonstrated that OS and PFI were significantly affected by all these parameters. Since single 7q- showed a better survival than the poor IPSS cytogenetic category (P=0.009), it was considered as a new prognostic entity ('modified IPSS categories'). In multivariate analysis OS was significantly influenced by age, marrow blast cell percentage, number of cytopenias and either modified or standard IPSS cytogenetic categories; hazard ratios for MDS/AML progression were influenced by all the former, except for age and cytopenias. Multivariate analysis of del(7)(q31q35) confirmed the results of univariate analysis, but the Akaike Information Criterion showed no difference in evaluating OS and PFI between the modified and standard IPSS cytogenetic grouping. In conclusion, (i) chromosome defects as grouped by IPSS and blast cell percentage are the most relevant parameters for predicting OS and PFI; (ii) the prognostic power of the IPSS cytogenetic grouping is not ameliorated by the introduction of del(7)(q31q35) as a new entity; (iii) complex karyotypes have a prognostic value independent of blast cell percentage. Leukemia (2005) 19, 1424-1431.

Entities:  

Mesh:

Year:  2005        PMID: 15920496     DOI: 10.1038/sj.leu.2403806

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  13 in total

1.  Prognosis in myelodysplastic syndromes: are the new classifications useful?

Authors:  Naomi Galili; Azra Raza
Journal:  Curr Hematol Malig Rep       Date:  2008-01       Impact factor: 3.952

Review 2.  Myelodysplastic Syndromes: Updates and Nuances.

Authors:  Kim-Hien T Dao
Journal:  Med Clin North Am       Date:  2017-03       Impact factor: 5.456

3.  Targeted re-sequencing analysis of 25 genes commonly mutated in myeloid disorders in del(5q) myelodysplastic syndromes.

Authors:  Marta Fernandez-Mercado; Adam Burns; Andrea Pellagatti; Aristoteles Giagounidis; Ulrich Germing; Xabier Agirre; Felipe Prosper; Carlo Aul; Sally Killick; James S Wainscoat; Anna Schuh; Jacqueline Boultwood
Journal:  Haematologica       Date:  2013-07-05       Impact factor: 9.941

4.  Lowering the boom on lower-risk myelodysplastic syndromes.

Authors:  Mikkael A Sekeres; Bhumika J Patel
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2019-12-06

5.  A critical role for phosphatase haplodeficiency in the selective suppression of deletion 5q MDS by lenalidomide.

Authors:  Sheng Wei; Xianghong Chen; Kathy Rocha; P K Epling-Burnette; Julie Y Djeu; Qing Liu; John Byrd; Lubomir Sokol; Nick Lawrence; Roberta Pireddu; Gordon Dewald; Ann Williams; Jaroslaw Maciejewski; Alan List
Journal:  Proc Natl Acad Sci U S A       Date:  2009-05-26       Impact factor: 11.205

6.  Efficacy and safety of lenalidomide in patients with myelodysplastic syndrome with chromosome 5q deletion.

Authors:  Vu H Duong; Rami S Komrokji; Alan F List
Journal:  Ther Adv Hematol       Date:  2012-04

Review 7.  Recent Advances in the 5q- Syndrome.

Authors:  Andrea Pellagatti; Jacqueline Boultwood
Journal:  Mediterr J Hematol Infect Dis       Date:  2015-05-20       Impact factor: 2.576

8.  Dramatic response in the dependency to transfusion after low doses of lenalidomide treatment in a 5q-syndrome patient: a case report.

Authors:  Mehmet Hilmi Dogu; Ismail Sari; Sibel Hacioglu; Ali Keskin
Journal:  North Clin Istanb       Date:  2015-01-24

9.  High Incidence of Gastrointestinal Ulceration and Cytogenetic Aberration of Trisomy 8 as Typical Features of Behçet's Disease Associated with Myelodysplastic Syndrome: A Series of 16 Consecutive Chinese Patients from the Shanghai Behçet's Disease Database and Comparison with the Literature.

Authors:  Yan Shen; Hai-Fen Ma; Dan Luo; Jian-Fei Cai; Jun Zou; Jian-Long Guan
Journal:  Biomed Res Int       Date:  2018-04-24       Impact factor: 3.411

Review 10.  How Ribosomes Translate Cancer.

Authors:  Sergey O Sulima; Isabel J F Hofman; Kim De Keersmaecker; Jonathan D Dinman
Journal:  Cancer Discov       Date:  2017-09-18       Impact factor: 39.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.